DYN

Dyne Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

Retrieved on: 
목요일, 5월 11, 2023
DYN, Muscular Dystrophy Association, Dystrophin, Duchenne muscular dystrophy, Therapy, Gene, DM1, Sarcolemma, Pharmacokinetics, American Academy, G&A, Oligonucleotide, Facial muscles, Biomarker, CNS, Sale, DMD, Patient, Enrollment, Episcopal conference, FORCE, Annual general meeting, Cell, MAD, R, Research, FDA, MDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, Society, Conference, Food, Transferrin, Pharmaceutical industry, Medical imaging, Cryptocurrency, Brain, Fibrosis, Dyne

WALTHAM, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the first quarter of 2023 and business highlights.

Key Points: 
  • (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the first quarter of 2023 and business highlights.
  • Research and development (R&D) expenses: R&D expenses were $37.5 million for the quarter ended March 31, 2023, compared to $28.2 million for the quarter ended March 31, 2022.
  • General and administrative (G&A) expenses: G&A expenses were $7.9 million for the quarter ended March 31, 2023, compared to $7.5 million for the quarter ended March 31, 2022.
  • Net loss: Net loss for the quarter ended March 31, 2023 was $44.2 million, or $0.78 per basic and diluted share.

Dyne Therapeutics to Present at BofA Securities 2023 Healthcare Conference

Retrieved on: 
수요일, 5월 3, 2023
DYN, Bank of America, BofA Securities, Therapy, Conference, Pharmaceutical industry, Online shopping

WALTHAM, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc .

Key Points: 
  • WALTHAM, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc .
  • (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the BofA Securities 2023 Healthcare Conference in Las Vegas on Wednesday, May 10, 2023 at 11:35 a.m. PT (2:35 p.m.
  • ET).
  • A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days following the presentation.

Dyne Therapeutics to Present New Preclinical Data at ASGCT Annual Meeting Demonstrating FORCE™ Platform Delivery to CNS

Retrieved on: 
화요일, 5월 2, 2023
DYN, Abstract, Central nervous system, Asian literature, Therapy, Gene, DM1, Brain, Cardiac muscle, CNS, CTG, FORCE, Annual general meeting, Deficit spending, Cell, DMPK, ASO, Phenotype, Society, Transferrin, Disease, Vaccine, Dyne

WALTHAM, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that new preclinical data demonstrating the FORCE™ platform achieved delivery to the central nervous system (CNS) and robust pharmacological effects in the brain will be featured in an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting, being held May 16-20, 2023 in Los Angeles.

Key Points: 
  • The FORCE platform was designed to overcome the limitations of delivering oligonucleotide therapeutics to muscle tissue by leveraging transferrin receptor 1 (TfR1).
  • TfR1-mediated delivery has also been shown by the field to facilitate uptake of therapeutics by the CNS.
  • In data to be presented at ASGCT, intravenous (IV) administration of FORCE conjugate achieved delivery to the CNS via TfR1 in both non-human primates (NHPs) and the innovative hTfR1/DMSXL mouse model.
  • “Our initial focus at Dyne has been to harness the power of the FORCE platform to deliver oligonucleotide therapeutics to muscle.

Dyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy

Retrieved on: 
목요일, 3월 23, 2023
China Biologic Products, DYN, Duchenne muscular dystrophy, Therapy, Food and Drug Administration, Clinical trial, Duchenne, DMD, Diagnosis, FDA, MPH, Second Half, Food, Pharmaceutical industry, Dyne

WALTHAM, Mass., March 23, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that DYNE-251, an investigational therapeutic for Duchenne muscular dystrophy (DMD) mutations amenable to exon 51 skipping, was granted U.S. Food and Drug Administration (FDA) orphan drug and rare pediatric disease designations. DYNE-251 is being evaluated in the Phase 1/2 DELIVER clinical trial.

Key Points: 
  • DYNE-251 is being evaluated in the Phase 1/2 DELIVER clinical trial.
  • “These regulatory designations highlight the urgent and critical need for new and better therapeutic options for people living with this fatal disease,” said Wildon Farwell, M.D., MPH, chief medical officer of Dyne.
  • “We are excited about DYNE-251 which we believe has the potential to transform the lives of people with DMD.
  • Under the FDA's rare pediatric disease designation program, the FDA may grant a priority review voucher to a sponsor who receives a product approval for a rare pediatric disease.

Dyne Therapeutics Announces Presentations on its DM1 and DMD Programs at the 2023 Muscular Dystrophy Association Clinical & Scientific Conference

Retrieved on: 
월요일, 3월 20, 2023
Myopathy, DYN, Muscular Dystrophy Association, Asian literature, Duchenne muscular dystrophy, Therapy, DM1, Sarcolemma, Poster, Episcopal conference, Dystrophin, MDA, Phenotype, MPH, Conference, Disease, Television, Pharmaceutical industry, Duchenne, DMD, Fibrosis, Dyne

WALTHAM, Mass., March 20, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced three poster presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference being held March 19-22, 2023, in Dallas, TX, and virtually.

Key Points: 
  • (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced three poster presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference being held March 19-22, 2023, in Dallas, TX, and virtually.
  • Dyne anticipates reporting initial data from these clinical trials in the second half of 2023.
  • These data build upon Dyne’s comprehensive preclinical data and further support the company’s ongoing development in DMD.
  • The posters will also be available in the Scientific Publications & Presentations section of Dyne’s website .

Dyne Therapeutics to Present at Upcoming Investor Conferences

Retrieved on: 
화요일, 3월 7, 2023
Stifel, DYN, Therapy, Conference, Pharmaceutical industry

WALTHAM, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc .

Key Points: 
  • WALTHAM, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc .
  • (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in virtual fireside chats at the following investor conferences:
    Oppenheimer 33rd Annual Healthcare Conference on Monday, March 13, 2023 at 2:40 p.m.
  • ET
    Stifel 2023 CNS Days on Wednesday, March 29, 2023 at 11:30 a.m.
  • ET
    Guggenheim Genomic Medicines and Rare Disease Days on Tuesday, April 4, 2023 at 10:10 a.m.

Dyne Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

Retrieved on: 
목요일, 3월 2, 2023
Myopathy, Safety, Rare disease, Episcopal conference, Facial muscles, Duchenne muscular dystrophy, Conference, Patient, DYN, MAD, Research, Therapy, Pharmacokinetics, DMD, G&A, Muscular Dystrophy Association, Dystrophin, DM1, MDA, R, Biomarker, Enrollment, Pharmaceutical industry, Medical imaging, Cryptocurrency, Dyne

WALTHAM, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the fourth quarter and full year 2022 and business highlights.

Key Points: 
  • WALTHAM, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the fourth quarter and full year 2022 and business highlights.
  • R&D expenses were $142.8 million and $121.3 million for the years ended December 31, 2022 and 2021, respectively.
  • Net loss: Net loss for the quarter ended December 31, 2022 was $38.8 million, or $0.74 per basic and diluted share.
  • Net loss for the year ended December 31, 2022 was $168.1 million, or $3.23 per basic and diluted share.

Dyne Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference

Retrieved on: 
화요일, 1월 3, 2023
Conference, DYN, Therapy, Pharmaceutical industry, Online shopping

WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc .

Key Points: 
  • WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc .
  • (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that Joshua Brumm, president and chief executive officer, is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 10, 2023 at 3:00 p.m. PT (6:00 p.m.
  • ET).
  • A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 30 days following the presentation.

Dyne Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

Retrieved on: 
목요일, 11월 3, 2022
G&A, Jude the Apostle, DMD, FDA, Investor, Adult, FSHD, University, Research, U.S. Securities and Exchange Commission, R, SEC, CA, FORCE, Food, MAD, GLOBE, Congress, University of Milan, Science, Dystrophin, Nucleic Acids Research, Duchenne muscular dystrophy, Security (finance), Patient, Muscle, Pharmacokinetics, DM1, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Degenerative disease, Private Securities Litigation Reform Act, Terminology, COVID-19, Review, National Institutes of Health Clinical Center, Hospital, Fast Track, Clinic, Nucleic acid, Therapy, Tissue, Safety, Conference, Facioscapulohumeral muscular dystrophy, Nasdaq, Form 10-Q, Credit, Credit Suisse, DYN, Center, Pharmaceutical industry, Medical imaging, Air cargo, Lease, Neurology, Dyne, Facebook

WALTHAM, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the third quarter of 2022 and business highlights.

Key Points: 
  • WALTHAM, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the third quarter of 2022 and business highlights.
  • In the third quarter of 2022 we marked incredibly important milestones for Dyne with the initiation of patient clinical trials for our two lead product candidates, DYNE-101 and DYNE-251.
  • In October 2022, Dyne announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for DYNE-251.
  • Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases.

Dyne Therapeutics to Present at Investor Conferences in November

Retrieved on: 
수요일, 11월 2, 2022
DM1, Credit, Duchenne muscular dystrophy, Conference, Dyne, GLOBE, Nasdaq, Facioscapulohumeral muscular dystrophy, DMD, Degenerative disease, Investor, Therapy, DYN, FSHD, Credit Suisse, CA, Pharmaceutical industry, Facebook

WALTHAM, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc .

Key Points: 
  • WALTHAM, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc .
  • (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to present at the following investor conferences in November:
    Credit Suisse 31st Annual Healthcare Conference, presentation on November 9, 2022 at 11:00 a.m. PT (2:00 p.m.
  • ET) in Rancho Palos Verdes, CA
    Jefferies London Healthcare Conference, fireside chat on November 16, 2022 at 12:20 p.m. GMT (7:20 a.m.
  • ET in New York
    Piper Sandler 34th Annual Healthcare Conference, fireside chat on November 29, 2022 at 11:00 a.m.